- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05095090
Study of Hospitalised Patients With Acute Respiratory Conditions (CHESTY)
Observational Cohort Study of Hospitalised Patients With Acute Respiratory Conditions
Study Overview
Status
Detailed Description
This will be an observational cohort study, recruiting patients who have been admitted to hospital with an acute respiratory condition. This can include exacerbation of an existing chronic lung disease such as asthma, COPD, interstitial lung disease, bronchiectasis and pleural disease, or contracting an acute illness including pulmonary embolism, pneumonia, or any other respiratory infection. The patients will be screened and recruited whilst still hospitalised and followed up for one year after discharge. The participants will undergo a baseline study visit while in hospital, with the option to have further follow up visits (up to three occasions) in the following year to assess clinical recovery.
The participants will be offered the choice to undertake the follow up assessments via any of the following routes:
- a telephone consultation or
- a face to face visit either in the Biomedical Research Centre (BRC) or
- during a research visit from another ethically approved study or
- during routine clinical follow up organised by the hospital clinical team.
The participants can choose not to attend any further follow up visits after discharge. Any planned clinical follow-up arranged by the hospital team will occur according to clinical needs. If the participant is re-admitted during the 12 months after enrolment, assessments identical to the baseline visit can be repeated.
A final remote visit will be carried out at 12 months post-discharge (+/- 1 month) to collect data about health care utilisation (e.g. hospitalisation rate, length of stay in hospital, death rate, antibiotic/steroid prescriptions) from both primary and secondary healthcare records. The participants are not required to attend this final visit as data will be collected remotely.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Leicester, United Kingdom, LE3 9QP
- Glenfield Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Hospitalised Patients
Inclusion Criteria:
- Hospital admission with an acute respiratory diagnosis
- Participant is willing & able to give informed consent for participation in the study
- Aged 18 years or above
- Able (in the Investigators opinion) & willing to comply with all study requirements
Exclusion Criteria:
- Unstable or life-threatening cardiac disease including myocardial infarction or unstable angina during current admission.
- Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
- Known pregnancy
Matched Controls
Inclusion Criteria:
- Aged 18 years or above
- Patients with stable chronic respiratory conditions or healthy volunteers
- Able (in the Investigators opinion) & willing to comply with all study requirements
7.3.2 Exclusion Criteria:
- Hospitalised due to an acute respiratory illness in the last 6 weeks prior to consent
- Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
- Known pregnancy
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Hospitalised Patients
Participants admitted to hospital with an acute respiratory condition including exacerbation of an underlying physician diagnosed chronic lung disease.
|
Matched Controls
The study will include matched controls (non-hospitalised patients with stable chronic respiratory conditions or healthy volunteers) to compare the exploratory endpoints.
The number of the matched controls will not exceed 25% of the main study recruitment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
30 days hospital re-admission rate
Time Frame: 30 days
|
To calculate the percentage of readmission due to the same acute respiratory illness within 30 days from consent
|
30 days
|
Length of index hospital admission stay
Time Frame: Variable (up to 52 weeks)
|
To calculate the length of the index hospital stay
|
Variable (up to 52 weeks)
|
30 days mortality rate
Time Frame: 30 days
|
To calculate the percentage of mortality within 30 days from consent
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total number of hospital readmission due to same underlying chronic lung disease.
Time Frame: 52 weeks
|
To evaluate the number of hospital readmission episodes due to same underlying chronic lung disease over a 52 weeks period.
|
52 weeks
|
Total number of non-hospitalised exacerbations of underlying chronic lung disease
Time Frame: 52 weeks
|
To evaluate the number of non-hospitalised exacerbations of chronic lung disease e.g.
asthma, Chronic Obstructive Pulmonary Diseases (COPD), etc. over 52 weeks
|
52 weeks
|
Time from consent to death (respiratory causes and all causes)
Time Frame: 52 weeks
|
To measure the time from consent to death within 52 weeks from consent.
This will include both respiratory and all causes of mortality
|
52 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of breathlessness using eMRC dyspnoea scale
Time Frame: 52 weeks
|
To evaluate the degree of breathlessness at baseline and following recovery from acute respiratory illness using Extended MRC dyspnoea scale(eMRC).
eMRC dyspnoea scale ranges from 1 to 5b with higher score indicates worse outcomes.
|
52 weeks
|
Assessment of quality of Life/symptoms using St. George's Respiratory Questionnaire (SGRQ)
Time Frame: 52 weeks
|
St. George's Respiratory Questionnaire (SGRQ) is a disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease.
Scores range from 0 to 100, with higher scores indicating more limitations.
|
52 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Neil Greening, PhD, MRCP, NIHR Respiratory Biomedical Research Centre, Leicester
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0822
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pneumonia
-
King Edward Memorial HospitalCompletedNosocomial Pneumonia | Healthcare-Associated Pneumonia | Aspiration Pneumonia | Ventilator-Associated PneumoniaIndia
-
Melinta Therapeutics, Inc.WithdrawnHospital-Acquired Bacterial Pneumonia | Ventilator-Associated Bacterial Pneumonia | Hospital-Acquired Pneumonia | Ventilator-Associated Pneumonia
-
Venatorx Pharmaceuticals, Inc.Biomedical Advanced Research and Development AuthorityNot yet recruitingHospital-acquired Pneumonia | Ventilator-associated Pneumonia
-
PfizerCompletedVentilator-associated Pneumonia (VAP) | Nosocomial Pneumonia (NP)Bulgaria, France, Italy, Korea, Republic of, Mexico, Peru, Poland, Russian Federation, Spain, Turkey, United Kingdom, Vietnam, Philippines, China, Ukraine, Argentina, Brazil, Hungary, Romania, India, Japan, Taiwan, Latvia, Czechia, Slov... and more
-
Arpida AGTerminatedHospital-Acquired Pneumonia | Ventilator-Associated Pneumonia | Health-Care-Associated Pneumonia
-
University Medical Centre LjubljanaUniversity of Ljubljana, Faculty of MedicineUnknownCommunity Acquired Pneumonia | Ventilator Associated Pneumonia | Hospital Acquired PneumoniaSlovenia
-
Hannover Medical SchoolCharite University, Berlin, Germany; University of LeipzigUnknownCOVID-19 | Bacterial Pneumonia | Viral Pneumonia | Pneumonia Due to Streptococcus Pneumoniae | Pneumonia Due to H. Influenzae | Pneumonia, Organism Unspecified | Pneumonia in Diseases Classified Elsewhere | Pneumonia Due to Other Specified Infectious OrganismsGermany
-
Nantes University HospitalSociété Française d'Anesthésie et de RéanimationCompletedPneumonia | Sepsis | Ventilator-Associated Pneumonia | Hospital Acquired PneumoniaFrance
-
ShionogiCompletedHospital Acquired Pneumonia (HAP) | Healthcare-associated Pneumonia (HCAP) | Ventilator Associated Pneumonia (VAP)Israel, Spain, United States, Belgium, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Japan, Latvia, Philippines, Puerto Rico, Russian Federation, Serbia, Taiwan, Ukraine
-
Avicenna Military HospitalCompletedHospital-acquired Pneumonia | Ventilator Associated Pneumonia | Community-acquired PneumoniaMorocco